Axsome Therapeutics, Inc. (AXSM) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Axsome Therapeutics is a hot idea with key upcoming FDA priority review of AXS-05 and NDA filing for AXS-12, strong Q3 revenue growth, and robust technical momentum. Despite operating losses and governance risks, its near-term regulatory catalysts provide potential for significant short-term price appreciation.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Deep Losses ⢠Heavy Leverage AXSM has strong liquidity and very high gross margins, but persistent losses, negative cash flow, and heavy leverage make its financial profile risky despite solid revenue scale.
Price Behavior
Key Price Behavior Insights: ⢠Uptrend intact ⢠Resistance test ⢠Support holding Support Level: $182-$184 Resistance Level: $189 AXSM has trended higher over the last month and is testing resistance near $189, with support around $182â$184; a breakout above resistance would confirm momentum, while a break below support would raise near-term caution.
Sentiment & News
Key News Insights: ⢠Moderate Buy ⢠Earnings catalyst ⢠Institutional interest Axsome Therapeutics is drawing broadly positive analyst and institutional interest, with a âModerate Buyâ consensus, a Q1 2026 earnings catalyst on deck, and the stock nearing a technical buy point.
AI Summary
AXSM has evolved from a pure pipeline bet into a real commercial growth story, but the investment still hinges on whether AUVELITY/SYMBRAVO momentum and SUNOSI's protected runway can scale fast enough to generate durable free cash flow before rising SG&A, leverage, and binary pipeline/regulatory risk catch up.
Description
Axsome Therapeutics is a U.S.-based biopharmaceutical company developing treatments for central nervous system disorders. Its late-stage pipeline includes a depression candidate (AXS-05) with additional trials in Alzheimer's-related agitation and prior smoking cessation data, a migraine treatment that completed Phase III testing (AXS-07), and Phase III programs for narcolepsy (AXS-12) and fibromyalgia (AXS-14). The company has a research collaboration with Duke University and was founded in 2012 in New York City.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 1 | Jan 8 | AXSM | Axsome Therapeutics, Inc. | Axsome Therapeutics is a hot idea with key upcoming FDA priority review of AXS-05 and NDA filing for AXS-12, strong Q3 revenue growth, and robust technical momentum. Despite operating losses and governance risks, its near-term regulatory catalysts provide potential for significant short-term price appreciation. | Closed | -8.3% |